A Phase IB/II Study of Durvalumab and Oleclumab Immunotherapy Combined with Standard Treatment for Patients with Colon Cancer

Share
Print

Full Title

A Phase 1b/2, Open-label, Multicenter Study of Novel Oncology Therapies in Combination with Chemotherapy and Bevacizumab as First-line Therapy in Metastatic Microsatellite-stable Colorectal Cancer (COLUMBIA-1)

Purpose

The purpose of this study is to assess the safety of giving the drugs durvalumab and oleclumab in combination with standard chemotherapy (FOLFOX treatment) and bevacizumab in patients with metastatic colorectal cancer who have not yet received treatment for advanced disease. All treatments are given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have metastatic colorectal cancer that has been genetically tested and does not have DNA repair errors (“microsatellite stable” disease).
  • Patients may not have previously received treatment for metastatic disease.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self-care, and capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Neil H. Segal at 646-888-4187.

Protocol

19-419

Phase

I/II

Investigator

Co-Investigators